Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ascendis Pharma reports strong revenue growth and market potential

Ascendis Pharma's financial performance in Q4 2022 showed revenue growth but operating losses, with a strong cash position.
Strengths lie in the TransCon technology platform, differentiation of products, and established commercial infrastructure.
Challenges include monitoring requirements, launch strategy comparisons, and market access strategies.
Opportunities arise from potential approvals, market dynamics, and clinical benefits of product candidates.

Ascendis Pharma reports robust Q1 revenue, faces regulatory challenges

Ascendis Pharma delivered a strong financial performance in Q1 2023, driven by revenue growth and strategic initiatives.
The company faces regulatory challenges and market dynamics that require resolution and strategic planning for sustained growth.
Opportunities for market expansion and product development exist through leveraging success factors and addressing regulatory hurdles.
Investor interest in Ascendis Pharma's future prospects is evident through analyst inquiries on growth expectations and market strategies.

Ascendis Pharma reports robust Q2 earnings amidst market challenges

Ascendis Pharma's Q2 performance reflects strong revenue generation and strategic advancements in key product pipelines, positioning the company for future growth.
Despite challenges in market shortages and regulatory processes, Ascendis Pharma's focus on innovation and market differentiation presents opportunities for expansion.
The company's emphasis on TransCon technology's unique benefits and market positioning underscores its competitive strength and growth potential in rare disease therapeutics.

Ascendis Pharma reports strong Q3 revenue growth and pipeline progress

Ascendis Pharma's Q3 2023 performance reflects revenue growth driven by SKYTROFA and progress in key pipeline programs.
The company's strategic focus on innovative therapies and patient-centric approaches positions it for future growth and market leadership.
While facing challenges like supply chain disruptions and market competition, Ascendis Pharma has opportunities for expansion and therapeutic innovation.
Balancing financial performance with pipeline advancement and commercial optimization will be crucial for Ascendis Pharma's sustainable success.

Ascendis Pharma excels in revenue growth and market leadership

Ascendis Pharma's strong performance in 2023, driven by SKYTROFA and TransCon PTH, positions the company for continued growth and success.
Despite challenges in market competition and treatment complexities, the company's strategic focus on patient outcomes and revenue growth is evident.
Opportunities in expanding therapeutic areas and maintaining market share stability offer potential for Ascendis Pharma's long-term success and value creation.

Ascendis Pharma reports robust Q1 performance and eyes global expansion

Ascendis Pharma's Q1 2024 performance reflects strong revenue growth, improved operational efficiency, and successful product launches, positioning the company for sustainable growth.
While facing challenges in market competition and financial targets, Ascendis Pharma's strategic strengths in product development and market expansion present growth opportunities.
The company's focus on innovation, commercial execution, and market positioning underscores its potential to become a leader in growth disorders and metabolic diseases.
Investors should monitor Ascendis Pharma's progress in achieving cash flow breakeven, expanding product portfolios, and navigating regulatory landscapes for future growth potential.

Ascendis Pharma excels in Q2 with YORVIPATH approval and revenue growth

Ascendis Pharma's Q2 2024 earnings call highlighted strong financial performance, successful product approvals, and strategic commercialization efforts.
The company faces challenges in pricing strategies, market dynamics, and ensuring patient uptake, but opportunities exist in expanding market reach and advancing pipeline programs.
Overall, Ascendis Pharma's focus on innovation, patient support, and financial growth positions it well for continued success and market leadership in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– European marketing application on track for third quarter 2020 submission – – European marketing application on track for third quarter 2020 submission –

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

-    In vitro data demonstrated selective binding and activation of IL-2 β/γ    receptor, associated with   reduced IL-2 α       receptor binding    -

Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020

When building your watchlist, focus on stocks with an 80 or higher RS Rating. Ascendis Pharma (ASND) is one stock that just reached the mark, now earning a score of 84. If it's not there already, put Ascendis Pharma stock on your watchlist.

Ascendis Pharma Clears Technical Benchmark, Hitting 80-Plus RS Rating

COPENHAGEN, Denmark, June  08, 2020  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations related to its rare disease endocrinology programs at ENDO Online 2020, the annual meeting of the Endocine Society, taking place June 8 - 22, 2020.

Ascendis Pharma A/S Announces Participation in ENDO Online 2020

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2020 Results - Earnings Call Transcript

COPENHAGEN, Denmark, May  11, 2020  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høiland as Global Chief Commercial Officer upon completion of his transition from Radius Health, Inc.

Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer

argenx

Axsome Therapeutics

Amicus Therapeutics

Iovance Biotherapeutics

Natera

United Therapeutics

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

7 “Strong Buy” Healthcare Stocks to Buy Now

– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects    within four weeks   –

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

COPENHAGEN, Denmark, April  15, 2020  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon hGH (lonapegsomatropin), as a treatment for growth hormone deficiency (GHD).

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2019 Results - Earnings Call Transcript

–    On track with 2020 corporate milestones –

Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

Ascendis Pharma (ASND) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Ascendis Pharma (ASND): Strong Industry, Solid Earnings Estimate Revisions

Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the Upgrade

Reata Pharmaceuticals

Sarepta Therapeutics

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2019 portfolio late last week, listing four new holdings.

Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter

COPENHAGEN, Denmark, Jan.  12, 2020  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma: Technology To Remove Stringency Of Dosage Regimen At Heart Of Success

Applied Materials

Apyx Medical Corp

Top Ranked Momentum Stocks to Buy for November 21st

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q3 2019 Results - Earnings Call Transcript

- Reflects company values and commitment to patients living with hypoparathyroidism -

Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

AC Immune

Eyenovia

Ngm Biopharmaceuticals Inc

SAGE Therapeutics

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

–    A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor    –

Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

Ascendis Pharma: Updates To Thesis, Q4 Data Looms

Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why

COPENHAGEN, Denmark, Oct.  21, 2019  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon Growth Hormone (hGH), a long-acting growth hormone therapy in development as a once-weekly treatment for pediatric growth hormone deficiency. TransCon hGH is designed to provide sustained release of unmodified growth hormone, the same growth hormone used in daily therapies, at a predictable rate over one week. Currently, there is no approved long-acting growth hormone treatment in Europe.

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

COPENHAGEN, Denmark, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate at the 2019 Cantor Global Healthcare Conference in October. Company executives will provide a business overview and update on the company’s pipeline programs.

News for Ascendis Pharma Stock (ASND)